AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Diffuse Large B Cell Lymphoma Refractory

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites๐Ÿ“ Gilbert๐Ÿ“ Scottsdale๐Ÿ“ Scottsdale Lyell Immunopharma, Inc. ยท Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049Phase 1, Phase 23 sites๐Ÿ“ Minneapolis๐Ÿ“ Columbus๐Ÿ“ Richmond Yazeed Sawalha ยท Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. NCT04915248Phase 218 sites๐Ÿ“ Ancona๐Ÿ“ Aviano๐Ÿ“ Florence Fondazione Italiana Linfomi - ETS ยท Tests: Daratumumab, Bortezomib, Dexamethasone Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) NCT06299553n/a1 site๐Ÿ“ Milan Incyte Biosciences Italy S.r.l Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726Phase 21 site๐Ÿ“ Seattle University of Washington ยท Tests: Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therโ€ฆ Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033Phase 253 sites๐Ÿ“ Anchorage๐Ÿ“ Clovis๐Ÿ“ Fullerton Hoffmann-La Roche ยท Tests: Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma NCT07126236Phase 219 sites๐Ÿ“ Seville๐Ÿ“ Zaragoza๐Ÿ“ Palma de Mallorca Grupo Espaรฑol de Linfomas y Transplante Autรณlogo de Mรฉdula โ€ฆ ยท Tests: Epcoritamab, Epcoritamab, tafasitamab and lenalidomide Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma NCT06649812Phase 2114 sites๐Ÿ“ Tucson๐Ÿ“ Tucson๐Ÿ“ Los Angeles National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients NCT04844866Phase 251 sites๐Ÿ“ Graz๐Ÿ“ Innsbruck๐Ÿ“ Linz Miltenyi Biomedicine GmbH ยท Tests: MB-CART2019.1, Standard of Care CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma NCT06209619Phase 11 site๐Ÿ“ Columbus Nathan Denlinger ยท Tests: Biopsy, Biospecimen Collection, Computed Tomography, Golcadomide, Positron Emission Tomography Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: biologic sample preservation procedure, cytology specimen collection procedure Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia NCT03418038Phase 24 sites๐Ÿ“ Mankato๐Ÿ“ Rochester๐Ÿ“ Eau Claire Mayo Clinic ยท Tests: Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone Hyperfractionated Dual Equivalent Fractionated Radiation Therapy NCT06898905NA1 site๐Ÿ“ New Haven Yale University ยท Tests: Bridging Radiation Therapy Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma NCT07198230n/a1 site๐Ÿ“ Fuzhou Ting YANG Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas NCT07478848Phase 11 site๐Ÿ“ Philadelphia Abramson Cancer Center at Penn Medicine ยท Tests: Vancomycin 125mg, Radiation Therapy, CAR-T Low Dose Epcoritamab Plus GemOx in R/R DLBCL NCT07451652Phase 21 site๐Ÿ“ Monterrey Hospital Universitario Dr. Jose E. Gonzalez ยท Tests: Epcoritamab, Gemcitabine (1000 mg/m2), Oxaliplatin An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT06517004Phase 11 site๐Ÿ“ Shanghai Fudan University ยท Tests: JWCAR201 Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma NCT05077527Phase 17 sites๐Ÿ“ Duarte๐Ÿ“ Chicago๐Ÿ“ New York AIDS Malignancy Consortium ยท Tests: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies NCT05836896Phase 11 site๐Ÿ“ Dresden Technische Universitรคt Dresden ยท Tests: MDC-CAR-BCMA001 (BCMA directed CAR T-cells) A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT07570017Phase 12 sites๐Ÿ“ Guangzhou๐Ÿ“ Shanghai Guangzhou Lupeng Pharmaceutical Company LTD. ยท Tests: Rocbrutinib, R-GemOx A Multicenter Observational Study to Understand the Clinical Characteristics, Treatment Patterns and Access to Novel Therapies of Patients With Diffuse Large B-Cell Lymphoma in the MEA Region NCT07065344n/a21 sites๐Ÿ“ Al Mansurah๐Ÿ“ Alexandria๐Ÿ“ Cairo AstraZeneca A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL NCT07409428Phase 350 sites๐Ÿ“ Shanghai๐Ÿ“ Baoding๐Ÿ“ Beijing Hutchmed ยท Tests: HMPL-760, HMPL-760 Placebo, R-GemOx A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites๐Ÿ“ Duarte๐Ÿ“ Orange๐Ÿ“ San Francisco Nurix Therapeutics, Inc. ยท Tests: NX-2127 Prospective Observational Study of Diffuse Large-cell B Lymphoma NCT06241729n/a1 site๐Ÿ“ Charleroi Grand Hรดpital de Charleroi ยท Tests: Algorithms to predict the probability of a primary refractory state Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma NCT07676877Phase 11 site๐Ÿ“ Columbus Nathan Denlinger ยท Tests: Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis Pembro Plus CAR T-cell Therapy in R/R in PMBCL NCT05934448Phase 22 sites๐Ÿ“ Boston๐Ÿ“ New York Jennifer Crombie, MD ยท Tests: Pembrolizumab, Lymphodepletion Chemotherapy, Chimeric Antigen Receptor (CAR) Therapy Infusion, Leukapheresis Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution NCT06131801n/a6 sites๐Ÿ“ Aurora๐Ÿ“ Atlanta๐Ÿ“ Cincinnati Children's Hospital Medical Center, Cincinnati ยท Tests: 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid)โ€ฆ NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) NCT07502118Phase 2, Phase 34 sites๐Ÿ“ Ankara๐Ÿ“ Ankara๐Ÿ“ Ankara Health Institutes of Turkey ยท Tests: Talikabtagene Autoleucel Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR NCT03676504Phase 1, Phase 22 sites๐Ÿ“ Heidelberg๐Ÿ“ Heidelberg University Hospital Heidelberg ยท Tests: CD19.CAR T Cells, Fludarabine, Cyclophosphamide Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies NCT05544968Phase 11 site๐Ÿ“ Milwaukee Medical College of Wisconsin ยท Tests: anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC), GM-CSF
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy